Products

Presentation:

Each 0.5 ml contains: Purified Typhoid Conjugate (Vi-DT) Vaccine INN containing purified Vi-capsular polysaccharide of Salmonella typhi 25 mcg conjugated to diphtheria toxoid.

Description:

Typhocon is a clear to slightly turbid liquid containing purified Typhoid Conjugate Bulk Antigen: 25 mcg (25 mcg of Vi polysaccharide of Salmonella typhi Ty2 conjugated to diphtheria toxoid ) This is T-cell dependent vaccine which induces Vi antibodies that neutralize Vi antigen unlike T-cell independent plain Vi polysaccharide vaccines.

Indications:

Typhocon is indicated for active immunization against typhoid fever for infants of ?6 months of age
or older and adults upto 45 years. Selective immunization with typhoid vaccine is recommended
for the following:

• Travelers to high endemic areas
• Household contact of carriers
• Healthcare personnel
  Police, armed forces and such other regimented personnel
• Laboratory workers who work with Salmonella typhi

Dosage and Administration:

Administration
The recommended dose of vaccine 0.5 ml is to administered intramuscularly.

Doses
The immunizing dose for adults, children and infants of ?6 months age or older and adults upto 45 years is single dose of 0.5 ml.

Revaccination
Booster dose may be given after 3 years

Side Effects:

Systemic adverse effects

• Common: ? 1% and < 10%: Fever, headache, diarrhea, nausea, vomiting
• Uncommon: ? 0.1% and < 1%: Itching, fatigue, malaise, myalgia, muscle ache, lethargy, persistent crying, general ache, arthralgia, drowsiness, loss of appetite, chills, rash, gastroenteritis, increased hepatic enzyme, rhinitis, bronchitis, acute respiratory tract infection, upper respiratory tract infection, pharyngitis, nasopharyngitis.

Local adverse effects

• Very Common: ? 10%: Pain at injection site, redness, soreness
• Common: ? 1% and < 10%: Tenderness, swelling at the injection site.

Precautions:

• Do not administer intravenously, intradermally, or subcutaneously.
• Typhoid conjugate vaccine protects against typhoid fever caused by Salmonella typhi Ty2.
• Protection is not conferred against Salmonella Paratyphi and other non-typhoidal Salmonellae.
• Epinephrine injection (1:1000) must be immediately available in case of an acute anaphylactic reaction or any allergic reaction occurs due to any component of the vaccine. The vaccinee should remain under medical supervision for not less than 30 minutes after vaccination. Like all other vaccines, supervision and appropriate medical treatment should always be available to treat any anaphylactic reactions following immunization

Commercial Pack:

Typhocon each box contains 1 pre-filled syringe of 0.5 ml Typhoid Conjugate Vaccine INN and 2
needles.